[Treatment of postmenopausal osteoporosis with low doses of calcitonin and a calcitonin-anabolic combination]. 1992

J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
Semmelweis Orvostudományi Egyetem, Budapest.

Menopausal osteoporotic women (age: 49-69, mean: 59.5 years) with crush fractures of the spine were treated with low doses of calcitonin (Miacalcic, 350 U/month), or with calcitonin + anabolic steroid (Retabolil, 50 mg/month). Efficacy of the therapy was controlled by single foton absorptiometry of midshaft and distal radius, by X-ray morphometry and by registering new crush fractures of the spine. Calcitonin monotherapy stopped further bone loss for two years, but at the end of the third year both absorptiometric values, as well as the radiomorphometrical index of the lumbar spine decreased significantly. In patients on calcitonin+anabolic steroid the decrease was just significant and only at radius midshaft, while at the other measured sites it was not. Two new crush fractures per 1396 patient-months occurred. Intermittent administration of low-dose calcitonin, especially together with an anabolic steroid seems to be a safe and effective therapy in established osteoporosis.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009277 Nandrolone C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position. 19-Nortestosterone,Estrenolone,Norandrostenolone,Nortestosterone,17-Hydroxy-Estr-4-Ene-3-One,17beta-Hydroxy-19-Nor-4-Androsten-3-One,17beta Hydroxy 19 Nor 4 Androsten 3 One
D002116 Calcitonin A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults. Thyrocalcitonin,Calcitonin(1-32),Calcitrin,Ciba 47175-BA,Eel Calcitonin,Calcitonin, Eel,Ciba 47175 BA,Ciba 47175BA
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005598 Fractures, Spontaneous Fractures occurring as a result of disease of a bone or from some undiscoverable cause, and not due to trauma. (Dorland, 27th ed) Fractures, Pathological,Fracture, Pathologic,Fracture, Pathological,Fractures, Pathologic,Pathological Fracture,Pathological Fractures,Fracture, Spontaneous,Pathologic Fracture,Pathologic Fractures,Spontaneous Fracture,Spontaneous Fractures
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077603 Nandrolone Decanoate Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS. 17 beta-Hydroxyestr-4-en-3-one 17-decanoate,19-Nortestosterone Decanoate,19-nor-4-Androstene-17 beta-ol-3-one 17-decanoate,Decadurabolin,Decadurobolin,Retabolil,Retabolyl,17 beta Hydroxyestr 4 en 3 one 17 decanoate,19 Nortestosterone Decanoate,19 nor 4 Androstene 17 beta ol 3 one 17 decanoate
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015663 Osteoporosis, Postmenopausal Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency. Bone Loss, Perimenopausal,Bone Loss, Postmenopausal,Perimenopausal Bone Loss,Postmenopausal Bone Loss,Postmenopausal Osteoporosis,Osteoporosis, Post-Menopausal,Bone Losses, Perimenopausal,Bone Losses, Postmenopausal,Osteoporoses, Post-Menopausal,Osteoporoses, Postmenopausal,Osteoporosis, Post Menopausal,Perimenopausal Bone Losses,Post-Menopausal Osteoporoses,Post-Menopausal Osteoporosis,Postmenopausal Bone Losses,Postmenopausal Osteoporoses

Related Publications

J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
June 1992, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
January 1984, Clinical endocrinology,
J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
September 1995, Clinical rheumatology,
J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
May 1987, Calcified tissue international,
J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
May 1976, Lancet (London, England),
J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
January 2015, Climacteric : the journal of the International Menopause Society,
J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
April 1982, Lancet (London, England),
J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
December 1987, Annals of internal medicine,
J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
September 1992, Orthopaedic review,
J Szücs, and C Horváth, and E Kollin, and M Szathmári, and I Holló
January 1996, Casopis lekaru ceskych,
Copied contents to your clipboard!